Updated Overall Survival by Circulating Tumor DNA Status from the Phase 3 IMvigor010 Trial: Adjuvant Atezolizumab Versus Observation in Muscle-invasive Urothelial Carcinoma

• DOI: 10.1016/j.eururo.2023.06.007
• Publication Date: 2023-07-26T05:16:08Z
• Authors: Thomas Powles; Zoe June Assaf; Viraj Degaonkar; Petros Grivas; Maha Hussain; Stephane Oudard; Jürgen E. Gschwend; Peter Albers; Daniel Castellano; Hiroyuki Nishiyama; Siamak Daneshmand; Shruti Sharma; Himanshu Sethi; Alexey Aleshin; Yi Shi; Nicole Davarpanah; Corey Carter; Joaquim Bellmunt; Sanjeev Mariathasan
• Keywords: Carcinoma, Transitional Cell; Treatment Outcome; Urinary Bladder Neoplasms; Adjuvants, Immunologic; Recurrence; Muscles; Antineoplastic Combined Chemotherapy Protocols; Humans; Prospective Studies; Neoplasm Recurrence, Local; Antibodies, Monoclonal, Humanized; 3. Good health; Circulating Tumor DNA

Interim results from IMvigor010 showed an overall survival (OS) benefit for adjuvant atezolizumab (anti-PD-L1) versus observation in patients with circulating tumor DNA (ctDNA)-positive muscle-invasive urothelial carcinoma (MIUC).To report updated OS and safety by ctDNA status.This ad hoc analysis from a global, open-label, randomized, phase 3 trial (NCT02450331) included intention-to-treat (ITT) population with evaluable cycle 1 day 1 (C1D1) ctDNA samples.Atezolizumab (1200 mg every 3 wk) or observation for ≤1 yr.OS, relapse rates, and safety by ctDNA status were assessed.Among 581 of 809 ITT patients included, 214 (37%) were ctDNA positive. Atezolizumab did not improve OS versus observation in ITT patients (hazard ratio [HR] 0.91 [95% confidence interval {CI} 0.73-1.13]; median follow-up 46.8 mo [interquartile range, 36.1-53.6]). In the observation arm, ctDNA positivity versus negativity was associated with shorter OS (HR 6.3 [95% CI 4.3-9.3]). The ctDNA positivity identified patients with an OS benefit favoring atezolizumab versus observation (HR 0.59 [95% CI 0.42-0.83]). A greater reduction in ctDNA levels with atezolizumab (C3D1) was associated with longer OS (100% clearance, 60.0 mo [95% CI 35.5-not estimable]; 50-99% reduction, 34.3 mo [95% CI 15.2-not estimable]; <50% reduction, 19.9 mo [95% CI 16.4-32.2]). The ctDNA positivity at C1D1 + C3D1 was associated with relapse with greater sensitivity than C1D1 alone (68% vs 57%). Adverse events were more frequent with atezolizumab than with observation, regardless of ctDNA status. A study limitation was its exploratory design.Evidence suggests that ctDNA positivity in MIUC predicts a benefit with atezolizumab. An in-progress prospective study will further evaluate these findings.Among patients with urothelial cancer after surgery, survival was poorer if tumor-derived DNA was detected in their bloodstream; these patients' survival was longer with atezolizumab versus observation. Bloodstream tumor-derived DNA may identify patients who benefit from atezolizumab.